Target validation for drug discovery in parasitic organisms.

Laurie K. Jackson, Margaret A. Phillips

Research output: Contribution to journalReview articlepeer-review

9 Scopus citations

Abstract

Parasite infections affect billions of humans world-wide, yet the current drugs available for the treatment of many parasitic diseases are either inadequate, or compromised by the development of resistance. Validation of a drug target is an important step in the development of new drugs. Target validation encompasses verifying that a target is primarily responsible for the therapeutic activity of a proven drug, or demonstrating the essential nature of a putative drug target in a parasite, and the capacity for selective inhibition of that target in vivo. Selective toxicity may be achieved by taking advantage of unique parasite biology or biochemistry, or by utilizing differences in metabolism or import. The essential nature of a target may be demonstrated by the correlation of the chemical or genetic reduction of target activity with the loss of parasite growth or virulence. Rescue experiments may demonstrate the single nature of a target. Ultimately, a target must be validated in vivo.

Original languageEnglish (US)
Pages (from-to)425-438
Number of pages14
JournalCurrent topics in medicinal chemistry
Volume2
Issue number5
DOIs
StatePublished - May 2002

ASJC Scopus subject areas

  • Drug Discovery

Fingerprint Dive into the research topics of 'Target validation for drug discovery in parasitic organisms.'. Together they form a unique fingerprint.

Cite this